Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

Market Cap	5.01B
Revenue (ttm)	542.45M
Net Income (ttm)	41.90M
Shares Out	120.00M
EPS (ttm)	0.35
PE Ratio	119.51
Forward PE	n/a
Dividend	0.10 (0.24%)
Ex-Dividend Date	Jun 9, 2025

Volume	26,233,294
Average Volume	24,368,261
Open	29.04
Previous Close	40.87
Day's Range	29.04 - 43.88
52-Week Range	14.61 - 46.75
Beta	0.19
RSI	70.62
Earnings Date	Aug 22, 2025

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefotiam hydrochloride, and adenosine monophosphate for injection; voglibose tablets, ansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; and raw materials, intermediates, and other products. Its products a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 548
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300584

Financial Performance

In 2024, SHE:300584's revenue was 504.36 million, a decrease of -2.60% compared to the previous year's 517.83 million. Earnings were 40.22 million, an increase of 10.75%.